USPTO 2015–2025 USPTO PatentsView US Corporation

Roche Diabetes Care, Inc.

USPTO PatentsView assignee record — 610 granted patents across 103 technology areas, active 2015–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61B (DIAGNOSIS; SURGERY; IDENTIFICATION).

610
Total patents granted
103
CPC technology areas
17.2
Avg claims per patent
-14%
5-year filing velocity

Portfolio overview

Roche Diabetes Care, Inc. has been granted 610 US utility patents between 2015 and 2025, placing Roche Diabetes Care, Inc. at rank #750 across all assignees tracked by PlainPatent. This portfolio spans 103 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.2 claims per patent with primary concentration in A61B (DIAGNOSIS; SURGERY; IDENTIFICATION). As a US Corporation, Roche Diabetes Care, Inc. is one of the broader-portfolio assignees in the PatentsView dataset. The composite Innovation Score of 62.0/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 282 grants, compared with 328 in the 2015–2019 window — a -14% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Roche Diabetes Care, Inc.'s 17.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a diversified footprint across 100+ CPC subclasses spreads risk across many technology fronts. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Roche Diabetes Care, Inc. against peers pursuing similar technology classes.

How does Roche compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Roche holds 610 patents — placing it at rank #750 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

USPTO utility patent grants by year · 2015–2025

20406080100 20152016201720182019202020212022202320242025 26
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Roche Diabetes Care, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 33 5.4%
2016 84 13.8%
2017 60 9.8%
2018 70 11.5%
2019 81 13.3%
2020 61 10.0%
2021 60 9.8%
2022 54 8.9%
2023 37 6.1%
2024 44 7.2%
2025 26 4.3%

Which technologies does Roche Diabetes Care, Inc. patent most?

Top 15 of 103 technology areas

Patent Moat Analysis

Portfolio Volume Moderate
Tech Breadth Diversified
Claim Depth Standard
Velocity Declining

Where it ranks

Overall rank by patents

#750

Across all tracked assignees

Innovation Score

62.0 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Roche Diabetes Care, Inc. hold?
Roche Diabetes Care, Inc. holds 610 US granted patents filed between 2015 and 2025, spanning 103 technology areas.
What is Roche Diabetes Care, Inc.'s Innovation Score?
Roche Diabetes Care, Inc. has an Innovation Score of 62.0 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Roche Diabetes Care, Inc. focus on?
Roche Diabetes Care, Inc.'s top technology area is A61B (DIAGNOSIS; SURGERY; IDENTIFICATION) with 306 patents. The company has filed patents in 103 CPC subclasses total.
Is Roche Diabetes Care, Inc.'s patent filing rate increasing or decreasing?
Roche Diabetes Care, Inc.'s recent filing velocity is -14% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Roche Diabetes Care, Inc.'s patents?
Roche Diabetes Care, Inc.'s patents average 17.2 claims each. This falls within the standard range, providing solid legal coverage.
How is the Roche Diabetes Care, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

All federal data sources used on this page
  • USPTO PatentsView — official U.S. Patent and Trademark Office bulk patent data. patentsview.org
  • USPTO Patent Application Information Retrieval (PAIR) — application status and file history. uspto.gov/patents/pair
  • USPTO Bulk Data Storage System — comprehensive patent text + claims dataset. bulkdata.uspto.gov
  • USPTO CPC Classification — Cooperative Patent Classification scheme for technology categorization. uspto.gov/cpc
  • SEC EDGAR — public filings cross-reference for assignee corporate entity matching. sec.gov/edgar
  • WIPO PATENTSCOPE — international patent context (related international filings). wipo.int/patentscope